News

Biogen's fourth quarter 2024 performance presents a complex picture for investors, with revenue climbing 2.9% to $2.46 billion and adjusted earnings per share reaching $3.44, surpassing market

Gilead Sciences witnessed a remarkable surge in its stock performance on Wednesday, with shares climbing over 8% to reach a new 52-week high of $104.64. The biotechnology company's impressive

Waters Corporation exceeded expectations in the fourth quarter of 2024, demonstrating robust financial performance across key metrics. The analytical instrument and laboratory technology specialist

EssilorLuxottica, the global leader in eyewear and optical products, has demonstrated remarkable financial performance in its latest fiscal year. The Franco-Italian eyewear giant reported a 4.4%

Pfizer and Astellas Pharma have achieved a significant breakthrough in advanced bladder cancer treatment, demonstrating remarkable success with their combination therapy of PADCEV and KEYTRUDA. The

The pharmaceutical giant Roche demonstrated market resilience as its stock recorded a modest uptick, closing with a 0.6 percent gain. The shares reached an intraday peak of 289.80 CHF, highlighting

The Novartis stock demonstrated robust performance on Monday at the Swiss Stock Exchange SIX, marking a significant upward trajectory throughout the trading session. The pharmaceutical giant's

Die Edwards Lifesciences Corporation steht heute im Fokus der Anleger, da der US-amerikanische Medizintechnikkonzern nach Börsenschluss seine Geschäftsergebnisse für das vierte Quartal 2024

Die niederländische Gesundheitstechnologiefirma Koninklijke Philips steht unmittelbar vor der Veröffentlichung ihrer Q4 2024 Ergebnisse am 19. Februar 2025. Der Konzern, der aktuell eine

Die Tochtergesellschaft UMR der UnitedHealth Group hat sich zu einer bedeutenden Zahlung von mindestens 20,3 Millionen Dollar bereit erklärt, um eine Auseinandersetzung mit dem US-Arbeitsministerium

Fresenius SE demonstrated remarkable momentum on the Frankfurt Stock Exchange today, with shares climbing 1.1 percent to reach €37.07. The stock, which opened at €36.50, achieved an intraday peak of

Fresenius Medical Care's stock demonstrated resilience in Friday's trading session, maintaining stability around the €47 mark throughout the day. Trading activity was notable, with over 180,000

Die Vertex Pharmaceuticals verzeichnet aktuell eine rückläufige Kursentwicklung an den Börsen. Der Biotech-Konzern, der sich auf die Entwicklung von Medikamenten für schwere Erkrankungen

Carl Zeiss Meditec experienced significant market pressure on Friday, with its shares displaying notable weakness during XETRA trading. Opening at €57.60, the stock faced downward momentum

Pfizer's recent quarterly performance demonstrates a significant turnaround, with revenues surging nearly 25% to reach $17.76 billion. The pharmaceutical giant has shown remarkable improvement in

Novartis experienced a notable decline on the Swiss SIX exchange Friday, with shares falling 0.4 percent to close at 97.31 CHF after touching a daily low of 96.87 CHF. The stock's movement attracted

Roche's stock demonstrated remarkable momentum on Friday at the Swiss SIX Exchange, climbing 0.8 percent to reach 290.10 CHF amid robust trading activity. The pharmaceutical giant's shares witnessed

Pfizer's stock experienced a modest decline of 0.8% to $26.24 in Thursday's New York trading session, yet the pharmaceutical giant's underlying performance tells a more compelling story. The company

Iqvia demonstrated robust performance in the fourth quarter of 2024, with revenue climbing 2.3% year-over-year to reach $3.96 billion. The company's Technology & Analytics Solutions segment emerged

Regeneron Pharmaceuticals has exceeded market expectations with its fourth-quarter performance, posting an adjusted earnings per share of $12.07, significantly surpassing analyst projections of

Danish pharmaceutical giant Novoordisk A/S exceeded market expectations with an impressive 37 percent surge in fourth-quarter profits, driving its stock price up by 4.5 percent. The company's